دورية أكاديمية
أعرض في EDS

Enhanced delivery of liposomes to lung tumor through targeting interleukin-4 receptor on both tumor cells and tumor endothelial cells.

التفاصيل البيبلوغرافية
العنوان: Enhanced delivery of liposomes to lung tumor through targeting interleukin-4 receptor on both tumor cells and tumor endothelial cells.
المؤلفون: Chi L; Department of Biochemistry and Cell Biology, Kyungpook National University, Daegu, Republic of Korea; BK21 Plus KNU Biomedical Convergence Program, Department of Biomedical Science, Kyungpook National University, Daegu, Republic of Korea; CMRI, Kyungpook National University, Daegu, Republic of Korea., Na MH; Department of Biochemistry and Cell Biology, Kyungpook National University, Daegu, Republic of Korea., Jung HK; Department of Biochemistry and Cell Biology, Kyungpook National University, Daegu, Republic of Korea; CMRI, Kyungpook National University, Daegu, Republic of Korea., Vadevoo SM; Department of Biochemistry and Cell Biology, Kyungpook National University, Daegu, Republic of Korea; BK21 Plus KNU Biomedical Convergence Program, Department of Biomedical Science, Kyungpook National University, Daegu, Republic of Korea; CMRI, Kyungpook National University, Daegu, Republic of Korea., Kim CW; Department of Biochemistry and Cell Biology, Kyungpook National University, Daegu, Republic of Korea; BK21 Plus KNU Biomedical Convergence Program, Department of Biomedical Science, Kyungpook National University, Daegu, Republic of Korea; CMRI, Kyungpook National University, Daegu, Republic of Korea., Padmanaban G; Department of Biochemistry and Cell Biology, Kyungpook National University, Daegu, Republic of Korea; CMRI, Kyungpook National University, Daegu, Republic of Korea., Park TI; Department of Pathology, Kyungpook National University, Daegu, Republic of Korea., Park JY; Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Republic of Korea., Hwang I; Dongsan Medical Center, Daegu, Republic of Korea., Park KU; Dongsan Medical Center, Daegu, Republic of Korea., Liang F; Industrial Technology Research Institute, HsinChu, Taiwan., Lu M; Industrial Technology Research Institute, HsinChu, Taiwan., Park J; Department of Bio and Brain engineering, KAIST, Daejeon, Republic of Korea., Kim IS; Biomedical Center, Korea Institute of Science and Technology, Seoul, Republic of Korea., Lee BH; Department of Biochemistry and Cell Biology, Kyungpook National University, Daegu, Republic of Korea; BK21 Plus KNU Biomedical Convergence Program, Department of Biomedical Science, Kyungpook National University, Daegu, Republic of Korea; CMRI, Kyungpook National University, Daegu, Republic of Korea. Electronic address: leebh@knu.ac.kr.
المصدر: Journal of controlled release : official journal of the Controlled Release Society [J Control Release] 2015 Jul 10; Vol. 209, pp. 327-36. Date of Electronic Publication: 2015 May 12.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Elsevier Science Publishers Country of Publication: Netherlands NLM ID: 8607908 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-4995 (Electronic) Linking ISSN: 01683659 NLM ISO Abbreviation: J Control Release Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Amsterdam : Elsevier Science Publishers, 1984-
مواضيع طبية MeSH: Lung Neoplasms/*metabolism , Oligopeptides/*administration & dosage , Receptors, Interleukin-4/*metabolism, Animals ; Antibiotics, Antineoplastic/administration & dosage ; Antibiotics, Antineoplastic/therapeutic use ; Cell Line, Tumor ; Doxorubicin/administration & dosage ; Doxorubicin/therapeutic use ; Human Umbilical Vein Endothelial Cells/drug effects ; Human Umbilical Vein Endothelial Cells/metabolism ; Humans ; Liposomes ; Lung Neoplasms/drug therapy ; Mice, Nude ; Oligopeptides/pharmacology ; Oligopeptides/therapeutic use
مستخلص: A growing body of evidence suggests that pathological lesions express tissue-specific molecular targets or biomarkers within the tissue. Interleukin-4 receptor (IL-4R) is overexpressed in many types of cancer cells, including lung cancer. Here we investigated the properties of IL-4R-binding peptide-1 (IL4RPep-1), a CRKRLDRNC peptide, and its ability to target the delivery of liposomes to lung tumor. IL4RPep-1 preferentially bound to H226 lung tumor cells which express higher levers of IL-4R compared to H460 lung tumor cells which express less IL-4R. Mutational analysis revealed that C1, R2, and R4 residues of IL4RPep-1 were the key binding determinants. IL4RPep-1-labeled liposomes containing doxorubicin were more efficiently internalized in H226 cells and effectively delivered doxorubicin into the cells compared to unlabeled liposomes. In vivo fluorescence imaging of nude mice subcutaneously xenotransplanted with H226 tumor cells indicated that IL4RPep-1-labeled liposomes accumulate more efficiently in the tumor and inhibit tumor growth more effectively compared to unlabeled liposomes. Interestingly, expression of IL-4R was high in vascular endothelial cells of tumor, while little was detected in vascular endothelial cells of control organs including the liver. IL-4R expression in cultured human vascular endothelial cells was also up-regulated when activated by a pro-inflammatory cytokine tumor necrosis factor-α. Moreover, the up-regulation of IL-4R expression was observed in primary human lung cancer tissues. These results indicate that IL-4R-targeting nanocarriers may be a useful strategy to enhance drug delivery through the recognition of IL-4R in both tumor cells and tumor endothelial cells.
(Copyright © 2015 Elsevier B.V. All rights reserved.)
فهرسة مساهمة: Keywords: IL-4 receptor; Liposomes; Lung tumor; Targeted drug delivery
المشرفين على المادة: 0 (Antibiotics, Antineoplastic)
0 (Liposomes)
0 (Oligopeptides)
0 (Receptors, Interleukin-4)
80168379AG (Doxorubicin)
تواريخ الأحداث: Date Created: 20150517 Date Completed: 20160321 Latest Revision: 20150606
رمز التحديث: 20221213
DOI: 10.1016/j.jconrel.2015.05.260
PMID: 25979323
قاعدة البيانات: MEDLINE
الوصف
تدمد:1873-4995
DOI:10.1016/j.jconrel.2015.05.260